Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats

Calcified Tissue International

Volumn 98, Issue 3, 2016, Pages 263-274

  Liu, Yang ^a   Rui, Yunfeng ^a   Cheng, Tin Yan ^c   Huang, Shuo ^a   Xu, Liangliang ^a   Meng, Fanbiao ^a   Lee, Wayne Yuk Wai ^a   Zhang, Ting ^a   Li, Nan ^c   Li, Chaoyang ^b   Ke, Huazhu ^b   Li, Gang ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b AMGEN INC   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fracture healing; Ovariectomy; Sclerostin antibody

Indexed keywords

ALKALINE PHOSPHATASE; MONOCLONAL ANTIBODY; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, RAT;

ALKALINE PHOSPHATASE COLONY FORMING UNIT ASSAY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE FORMATION RATE; BONE MASS; BONE STRENGTH; CALLUS; CELL DIFFERENTIATION; CFU COUNTING; CONTROLLED STUDY; DYNAMIC BONE FORMATION; ESTROGEN DEFICIENCY; FEMALE; FEMUR FRACTURE; FOUR POINT BENDING MECHANICAL TESTING; FRACTURE HEALING; HEMATOPOIETIC STEM CELL; MECHANICAL STIMULUS TEST; MICRO-COMPUTED TOMOGRAPHY; MINERAL APPOSITION RATE; MINERALIZING SURFACE; MORPHOMETRICS; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; ANIMAL; BONE DEVELOPMENT; BONE MARROW CELL; CHEMISTRY; CYTOLOGY; DIAGNOSTIC IMAGING; GENETIC MARKER; IMMUNOLOGY; MECHANICAL STRESS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SPRAGUE DAWLEY RAT; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

ALKALINE PHOSPHATASE; ANIMALS; ANTIBODIES; BODY WEIGHT; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEINS; FEMALE; FEMORAL FRACTURES; FRACTURE HEALING; GENETIC MARKERS; INJECTIONS, SUBCUTANEOUS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOGENESIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; STEM CELLS; STRESS, MECHANICAL; X-RAY MICROTOMOGRAPHY;

EID: 84957839379     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-015-0085-3     Document Type: Article

References (40)

1. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767
2. Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3–S7
3. Ke HZ et al (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747–783
4. McKibbin B (1978) The biology of fracture healing in long bones. J Bone Joint Surg Br 60-B(2):150–162
5. Frost HM (1989) The biology of fracture healing. An overview for clinicians. Part I. Clin Orthop Relat Res 248:283–293
6. Li X et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578–588
7. Ring D et al (2004) Locking compression plates for osteoporotic nonunions of the diaphyseal humerus. Clin Orthop Relat Res 425:50–54
8. Hill TP et al (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8(5):727–738
9. Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13(4):485–496
10. Komatsu DE et al (2010) Modulation of Wnt signaling influences fracture repair. J Orthop Res 28(7):928–936
11. Zhang R et al (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52(1):145–156
12. Kamiya N et al (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135(22):3801–3811
13. Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209
14. Ten Dijke P et al (2008) Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90(Suppl 1):31–35
15. Van Bezooijen RL et al (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22(1):19–28
16. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589
17. Balemans W, Ebeling M, Patel N (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537–543
18. Kramer I et al (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25(2):178–189
19. McDonald MM et al (2012) Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 30(10):1541–1548
20. Padhi D et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19–26
21. Bonnarens Frank, Einhorn TA (1984) Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2(1):97–102
22. Mittra E et al (2008) Evaluation of trabecular mechanical and microstructural properties in human calcaneal bone of advanced age using mechanical testing, microCT, and DXA. J Biomech 41(2):368–375
23. Suen PK et al (2014) Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J Orthop Res 32(8):997–1005
24. Dempster DW et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2–17
25. He YX et al (2011) Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: a drill-hole defect model. Bone 48(6):1388–1400
26. He YX et al (2012) Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model. Osteoporos Int 23(1):377–389
27. Xu L et al (2012) Cellular retinol-binding protein 1 (CRBP-1) regulates osteogenenesis and adipogenesis of mesenchymal stem cells through inhibiting RXRalpha-induced beta-catenin degradation. Int J Biochem Cell Biol 44(4):612–619
28. Augat P et al (2005) Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 16(Suppl 2):S36–S43
29. Ominsky MS et al (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26(5):1012–1021
30. Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S, Posvar E (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res S1:S37
31. Hamann C et al (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28(3):627–638
32. Saito M et al (2010) Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 46(4):1170–1179
33. Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low trauma fracture in men and women. JAMA 297(4):387–394
34. Heino TJ, Hentunen TA (2008) Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther 3(2):131–145
35. Farley JR, Baylink DJ (1986) Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metabolism 35(6):563–572
36. Sutherland MK et al (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35(4):828–835
37. Winkler DG, Sutherland MK, Geoghegan JC (2003) Osteocyte control of bone formation via sclerostin. EMBO J 22(23):6267–6276
38. Jacobsen KA et al (2008) Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 23(5):596–609
39. Street J et al (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99(15):9656–9661
40. Lu C, Marcucio R, Miclau T (2006) Assessing angiogenesis during fracture healing. Iowa Orthop J 26:17–26